PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Irinotecan plus capecitabine

First Posted Date: 2008-03-13

Last Posted Date: 2008-04-07

Lead Sponsor: Pfizer

Target Recruit Count: 73

Registration Number: NCT00635323

Locations: 🇨🇳
Pfizer Investigational Site, Taipei, Taiwan

Efficacy of Somatropin in Adult Patients With Isolated Growth Hormone Deficiency

Phase 3

Terminated

Conditions: Growth Hormone Deficiency

Interventions: Drug: Placebo
Drug: Somatropin

First Posted Date: 2008-03-07

Last Posted Date: 2013-03-04

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT00630487

Locations: 🇩🇪
Pfizer Investigational Site, Muenchen, Germany

A Study of the Efficacy and Safety of Aricept in Patients With Severe Alzheimer's Disease Who Are Living in Skilled Nursing Homes

Phase 3

Completed

Conditions: Alzheimer Disease

Interventions: Drug: Donepezil (Aricept)
Drug: Placebo

First Posted Date: 2008-03-07

Last Posted Date: 2015-03-05

Lead Sponsor: Pfizer

Target Recruit Count: 249

Registration Number: NCT00630851

Locations: Pfizer Investigational Site

Study Of Sunitinib In Combination With Folfox In Patients With Colorectal Cancer

Phase 1

Completed

Conditions: Colorectal Neoplasms

Interventions: Drug: sunitinib + mFOLFOX6

First Posted Date: 2008-03-07

Last Posted Date: 2011-03-16

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT00631410

Locations: 🇯🇵
Pfizer Investigational Site, Chuo-ku, Tokyo, Japan

Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects

Phase 3

Completed

Conditions: Renal Cell Carcinoma

Interventions: Drug: Bevacizumab
Drug: Interferon-Alfa 9MU
Drug: Temsirolimus

First Posted Date: 2008-03-07

Last Posted Date: 2016-04-27

Lead Sponsor: Pfizer

Target Recruit Count: 791

Registration Number: NCT00631371

Locations: 🇭🇺
Uzsoki Utcai Korhaz, Budapest, Hungary
🇨🇱
Fundacion Arturo Lopez Perez, Santiago, Chile
🇭🇰
Pamela Youde Nethersole Eastern Hospital, Chai Wan, Hong Kong

and more 166 locations

The Effects of Fx-1006A on Transthyretin Stabilization and Clinical Outcome Measures in Patients With Non-V30M Transthyretin Amyloidosis

Phase 2

Completed

Conditions: Transthyretin-associated Amyloidosis With Polyneuropathy

Interventions: Drug: Fx-1006A

First Posted Date: 2008-03-07

Last Posted Date: 2013-01-18

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT00630864

Locations: 🇫🇷
CHU de Bicetre, Paris, France
🇺🇸
Johns Hopkins Hospital, Baltimore, Maryland, United States
🇩🇪
Universitatsklinikum Munster, Transplant Hepatology, Munster, Germany

and more 1 locations

Transthyretin Amyloidosis Outcome Survey (THAOS)

Completed

Conditions: Transthyretin Gene Mutations
Transthyretin Amyloidosis

Interventions: Other: None. Observational Study.

First Posted Date: 2008-03-05

Last Posted Date: 2024-11-22

Lead Sponsor: Pfizer

Target Recruit Count: 6718

Registration Number: NCT00628745

Locations: 🇺🇸
The University of Utah Health Sciences Center, Salt Lake City, Utah, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇦🇷
Hospital Italiano de Buenos Aires (HIBA), Buenos Aires, Argentina

and more 109 locations

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

Phase 2

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Drug: CE-224,535
Drug: Placebo

First Posted Date: 2008-03-04

Last Posted Date: 2022-04-04

Lead Sponsor: Pfizer

Target Recruit Count: 100

Registration Number: NCT00628095

Locations: 🇺🇸
University Physicians, Columbia, Missouri, United States
🇺🇸
University of Missouri-Columbia, Columbia, Missouri, United States
🇺🇸
New Horizons Clinical Research, Cincinnati, Ohio, United States

and more 23 locations

Genotropin Treatment In Very Young Children Born Small For Gestational Age

Phase 3

Completed

Conditions: Infant, Small for Gestational Age

Interventions: Drug: Genotropin (PN-180,307) Somatropin
Drug: Control-no treatment

First Posted Date: 2008-03-03

Last Posted Date: 2014-11-04

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00627523

Locations: 🇮🇹
Policlinico Universitario, Istituto di Clinica Pediatrica, Messina, Italy
🇸🇪
Drottning Silvias Barn och Ungdomssjukhus, Göteborg, Sweden
🇮🇹
Dipartimento di Medicina Pediatrica, UO di Endocrinologia e Diabetologia, Roma, Italy

and more 14 locations

A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS

Phase 3

Completed

Conditions: Restless Legs Syndrome

Interventions: Drug: Cabergoline
Other: Placebo

First Posted Date: 2008-02-29

Last Posted Date: 2011-04-25

Lead Sponsor: Pfizer

Target Recruit Count: 43

Registration Number: NCT00627003

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy